David A. Siegel
Pharmacy at Holly St, Denver, CO

License number
Colorado 12582
Issued Date
Aug 4, 1988
Renew Date
Oct 31, 1997
Expiration Date
Oct 31, 1997
Type
Pharmacist
Address
Address
1068 Holly St, Denver, CO 80220
LicenseFiles verified this license of Dec 9, 2016 at the Colorado - Department of Regulatory Agencies.

Professional information

David Siegel Photo 1

President &Amp; Ceo At Frontier Airlines
Position:
President & CEO at Frontier Airlines
Location:
Greater Denver Area
Industry:
Aviation & Aerospace
Work:
Frontier Airlines - Denver, CO since Jan 2012 - President & CEO Hyannisport Capital Jun 2010 - Jan 2012 - Managing Director XOJET - San Francisco Bay Area Oct 2008 - May 2010 - Chairman & CEO Gategroup Apr 2004 - Apr 2009 - Chairman & CEO G2 Switchworks 2006 - 2008 - Chairman US Airways Mar 2002 - May 2004 - President & CEO Avis Budget Group 1999 - 2002 - Chairman & CEO Continental Express 1994 - 1999 - President & CEO Northwest Airlines 1991 - 1993 - Director Bain & Company 1983 - 1989 - Consultant
Education:
Harvard Business School 1985 - 1987
MBA, General Management Brown University 1979 - 1983
Sc.B., Applied Math - Economics LSE

David Siegel Photo 2

Business Executive At Level 3
Location:
Greater Denver Area
Industry:
Telecommunications
Skills:
Network Design, Business Planning, Product Strategies, Managed Services, IP, MPLS, Product Management, VoIP, Network Architecture, Vendor Management, Product Marketing, Strategic Partnerships, SIP, Leadership, DNS, Cisco IOS, Ethernet, WAN, Integration, Project Management, Networking, Enterprise Software, Co-location, Network Engineering, Management, Frame Relay, Routing, Security, Network Security, VPN, Broadband, Virtualization, Network Administration, BGP, Routers, Unix, Switches, OSPF

David Siegel Photo 3

Associate Professor At University Of Colorado Health Sciences Center
Position:
Co-Director at QGenta Inc., Research Associate Professor at University of Colorado Health Sciences Center
Location:
Greater Denver Area
Industry:
Research
Work:
QGenta Inc. since Jan 2008 - Co-Director University of Colorado Health Sciences Center since Jan 2005 - Research Associate Professor
Education:
School of Pharmacy, University of Colorado 1988 - 1993
Ph.D., Pharmaceutical Sciences School of Pharmacy, University of Colorado 1985 - 1988
B.S., Pharmacy University of Colorado Boulder 1978 - 1983
B.A., Molecular Cellular & Developmental Biology

David Siegel Photo 4

Hsp90 Inhibitors With Modified Toxicity

US Patent:
8551964, Oct 8, 2013
Filed:
Aug 22, 2008
Appl. No.:
12/673996
Inventors:
David Ross - Boulder CO, US
David Siegel - Denver CO, US
Wenchang Guo - Elk Grove CA, US
Christopher J. Moody - Leeds, GB
Christopher S. P. McErlean - Eden's Landing, AU
Assignee:
The Regents of the University of Colorado - Denver CO
International Classification:
A61K 31/704
US Classification:
514 34
Abstract:
The invention provides 19-substituted geldanamycin derivatives, pharmaceutically acceptable salts thereof and prodrugs thereof that are potent Hsp90 binding agents useful for the treatment of, and/or the amelioration of symptoms of, cancer and other proliferative tissue disorders.

David Siegel Photo 5

Indole Derivatives And Methods Of Using The Same

US Patent:
2009022, Sep 10, 2009
Filed:
Feb 27, 2006
Appl. No.:
11/908395
Inventors:
David Ross - Boulder CO, US
Philip Reigan - Northunberland, GB
David Siegel - Denver CO, US
Christopher J. Moody - Leicestershire, GB
Marie A. Colucci - Nottingham, GB
Donna Dehn - Castle Rock CO, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO - Denver CO
International Classification:
A61K 31/404, C07D 209/12, C12N 5/06, A61P 35/00
US Classification:
514415, 548509, 435375
Abstract:
The invention provides indole-4,7-dione derivatives useful for the treatment of diseases in a mammal, pharmaceutical compositions containing the same and methods of using the same in the treatment of cancer and neoplastic diseases including human solid tumors and other mammalian tumors.

David Siegel Photo 6

Dt-Diaphorase Directed Anti-Tumor Agents

US Patent:
6156744, Dec 5, 2000
Filed:
May 24, 1999
Appl. No.:
9/317906
Inventors:
David Ross - Boulder CO
John Butler - Stockport, GB
Robert H. J. Hargreaves - Bury, GB
David Siegel - Denver CO
Howard D. Beall - Missoula MT
Assignee:
Cancer Research Campaign Tech (London)
University Technology Corp. - Boulder CO
University of Salford - Boulder CO
International Classification:
A61K 31396, C07D40302, C07D40308
US Classification:
514183
Abstract:
The present invention relates to a novel benzoquinone, 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone and its esters. The compounds can be used to treat tumors exhibiting elevated levels of the enzyme DT-diaphorase.

David Siegel Photo 7

Hsp90 Inhibitors, Methods Of Making And Uses Therefor

US Patent:
7608611, Oct 27, 2009
Filed:
Aug 31, 2005
Appl. No.:
11/218320
Inventors:
David Ross - Boulder CO, US
David Siegel - Denver CO, US
Philip Reigan - Denver CO, US
Wenchang Guo - Denver CO, US
Daniel L. Gustafson - Denver CO, US
Assignee:
The Regents of the University of Colorado - Denver CO
International Classification:
A01N 43/00, A61K 31/33, C07D 225/00, C07D 295/00
US Classification:
514183, 540450
Abstract:
The invention provides purified 18,21-didehydro-18,21-dideoxo-18,21-dihydroxy-geldanamycin derivatives, pharmaceutically acceptable salts thereof and prodrugs thereof that are potent Hsp90 binding agents that are useful for the treatment and/or the amelioration of symptoms of cancer and other proliferative tissue disorders.

Pharmacy licenses in Colorado










Other Doctors licenses in Colorado